SciSparc (SPRC) Income from Continuing Operations (2016 - 2022)
SciSparc (SPRC) posted Income from Continuing Operations of 359000.0 for Q4 2022, down 113.14% sequentially from 2732000.0 in Q3 2022.
SciSparc (SPRC) Income from Continuing Operations (2016 - 2022) Analysis & Trends
SciSparc has reported Income from Continuing Operations for 5 years, with the latest figure at 359000.0 in Q4 2022.
- Quarterly Income from Continuing Operations changed N/A year-over-year to 359000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was 4422000.0 (changed N/A YoY) and the FY2025 annual result came in at 12564000.0, down 68.15% from the prior year.
- Income from Continuing Operations slipped to 359000.0 in Q4 2022 per SPRC's latest filing, from 2732000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2732000.0 in Q3 2022 and troughed at 12334000.0 in Q4 2018.
- A 3-year average of 1020500.0 and a median of 140500.0 in 2018 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2018 and 2019: Income from Continuing Operations slumped 79.48% in 2018, then jumped 2104.76% in 2019.
- Over 3 years, Income from Continuing Operations stood at 12334000.0 in 2018, then surged by 101.6% to 197000.0 in 2019, then plunged by 282.23% to 359000.0 in 2022.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 359000.0, 2732000.0, and 197000.0 for Q4 2022, Q3 2022, and Q2 2019 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 164.49 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -13.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -174.37 Mn |
| 10 | SciSparc | 836,385.99 | 836,385.99 | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -359,000.00 |
| Sep 30, 2022 | 2.73 Mn |
| Jun 30, 2019 | 197,000.00 |
| Mar 31, 2019 | 1.85 Mn |
| Dec 31, 2018 | -12.33 Mn |
| Sep 30, 2018 | 1.14 Mn |
| Jun 30, 2018 | -1.48 Mn |
| Mar 31, 2018 | 84,000.00 |
| Dec 31, 2017 | -6.87 Mn |
| Sep 30, 2017 | -116,000.00 |
| Jun 30, 2017 | -1.74 Mn |
| Mar 31, 2017 | -315,000.00 |
| Dec 31, 2016 | -1.97 Mn |
| Sep 30, 2016 | -17,000.00 |
| Jun 30, 2016 | -18,000.00 |